Core Insights - Evogene, Systasy, and LMU University Hospital Munich have announced a collaboration to develop novel therapies for neutrophil-derived inflammatory diseases, supported by a pan-European EUREKA grant [1][2][3] - The collaboration aims to address the unmet need for safe and effective treatments for inflammatory bowel disease (IBD) and other hyper-inflammatory diseases driven by dysregulated neutrophil activity [1][2] - The project leverages the expertise of each partner, with Evogene leading small-molecule drug discovery using its ChemPass AI™ generative engine, while Systasy will enhance its PathwayProfiler™ platform for profiling stem cell-derived neutrophils [1][2][3] Company Contributions - Evogene will utilize its proprietary ChemPass AI™ to design, optimize, and prioritize novel inhibitors, integrating computational design with high-throughput experimental validation in collaboration with the Weizmann Institute of Science [1][2] - Systasy will expand its PathwayProfiler™ platform to generate high-dimensional functional data for validating Evogene's AI-designed inhibitors, enhancing the drug discovery process [1][2][3] - LMU University Hospital, led by Prof. Christoph Klein, will apply advanced stem cell biology and precision diagnostics to validate lead compounds and support biomarker discovery [1][2][3] Industry Context - The collaboration addresses a significant global health issue, as hundreds of millions are affected by inflammatory and immune-mediated diseases where neutrophils play a key pathogenic role [1][2] - Current therapies do not directly target neutrophils, highlighting the need for innovative treatment approaches that can modulate excessive neutrophil-driven inflammation [1][2] - The integration of AI-driven discovery with clinical insights aims to advance therapeutic concepts with clear clinical and commercial potential, reflecting a trend towards personalized medicine in immunology [1][2][3]